Department of Anesthesiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Ther Hypothermia Temp Manag. 2024 Sep;14(3):130-143. doi: 10.1089/ther.2023.0033. Epub 2023 Aug 11.
There is a paucity of evidence regarding the utility of targeted temperature management (TTM) in COVID-19 patients who suffer cardiac arrest. This systematic review and meta-analysis aimed to use the available data of how temperature predicts outcomes in COVID-19 patients and the association between active cooling and outcomes in non-COVID-19 cardiac arrest patients to give recommendations for the utility of TTM in COVID-19 survivors of cardiac arrest. The PubMed, Embase, and Web of Science databases were queried in August 2022 for two separate searches: (1) temperature as a predictor of clinical outcomes in COVID-19 and (2) active cooling after return of spontaneous circulation (ROSC) in non-COVID-19. Forest plots were generated to summarize the results. Of the 4209 abstracts screened, none assessed the target population of TTM in COVID-19 victims of cardiac arrest. One retrospective cohort study evaluated hyperthermia in critically ill COVID-19 patients, two retrospective cohort studies evaluated hypothermia in septic COVID-19 patients, and 20 randomized controlled trials evaluated active cooling in non-COVID-19 patients after ROSC. Risk of death was higher in COVID-19 patients who presented with hyperthermia (risk ratio [RR] = 1.87) or hypothermia (RR = 1.77; < 0.001). In non-COVID-19 victims of cardiac arrest, there was no significant difference in mortality (RR = 0.94; = 0.098) or favorable neurological outcome (RR = 1.05; = 0.41) with active cooling after ROSC. Further studies are needed to evaluate TTM in COVID-19 victims of cardiac arrest. However, given the available evidence that hyperthermia or hypothermia in COVID-19 patients is associated with increased mortality as well as our findings suggesting limited utility for active cooling in non-COVID-19 cardiac arrest patients, we posit that TTM to normothermia (core body temperature ∼37°C) would most likely be optimal for the best outcomes in COVID-19 survivors of cardiac arrest.
关于 COVID-19 患者心脏骤停后接受目标温度管理(TTM)的效果,相关证据有限。本系统评价和荟萃分析旨在利用现有数据,即体温如何预测 COVID-19 患者的结局,以及非 COVID-19 心脏骤停患者主动复温与结局之间的关联,为 COVID-19 心脏骤停幸存者 TTM 的应用提供建议。2022 年 8 月,我们在 PubMed、Embase 和 Web of Science 数据库中进行了两次独立检索:(1)体温作为 COVID-19 患者临床结局的预测指标,(2)非 COVID-19 心脏骤停患者自主循环恢复(ROSC)后主动复温。生成森林图以总结结果。在筛选出的 4209 篇摘要中,没有一篇评估了 TTM 在 COVID-19 心脏骤停受害者中的目标人群。一项回顾性队列研究评估了危重症 COVID-19 患者的高热,两项回顾性队列研究评估了脓毒症 COVID-19 患者的低温,20 项随机对照试验评估了非 COVID-19 患者 ROSC 后的主动复温。出现高热(风险比 [RR] = 1.87)或低温(RR = 1.77; < 0.001)的 COVID-19 患者死亡率更高。非 COVID-19 心脏骤停患者,ROSC 后主动复温与死亡率(RR = 0.94; = 0.098)或良好神经结局(RR = 1.05; = 0.41)无显著差异。需要进一步研究来评估 COVID-19 心脏骤停患者的 TTM。然而,鉴于现有证据表明 COVID-19 患者的高热或低温与死亡率增加有关,以及我们的研究结果表明非 COVID-19 心脏骤停患者主动复温的效用有限,我们推测 TTM 至正常体温(核心体温约 37°C)可能最有利于 COVID-19 心脏骤停幸存者获得最佳结局。